Rheumatic Joint Disease clinical trials at UCSF
1 in progress, 1 open to new patients
open to eligible people ages 2–21
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
San Francisco, California and other locations